Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 11/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MITF | O75030 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 2/20 | 0.36 |
| ▸ | CDK8 | P49336 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13457594 | 1.00 | MAPT (0.42) | MAPTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL13457878 | 0.85 | KDM4E (0.40) | TDP1KMT2AHTTCDK8NPSR1 | |
| SCHEMBL12367241 | 0.85 | KDM4E (0.40) | TDP1KMT2AHTTCDK8NPSR1 | |
| SCHEMBL27824183 | 0.84 | L3MBTL1 (0.36) | MAPTALDH1A1TDP1LMNASMN1; SMN2 | |
| SCHEMBL27824185 | 0.84 | POLB (0.36) | MAPTALDH1A1TDP1KMT2AMEN1 | |
| SCHEMBL2207377 | 0.83 | BTK (0.45) | — | |
| SCHEMBL2207373 | 0.83 | BTK (0.45) | — | |
| SCHEMBL12367223 | 0.79 | PKM (0.44) | MAPTALDH1A1TDP1KMT2AHTT | |
| SCHEMBL27843182 | 0.72 | IDE (0.37) | ALDH1A1 | |
| SCHEMBL27843186 | 0.71 | BTK (0.35) | ALDH1A1KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735424-B2 | Bicyclic kinase inhibitors | NOVARTIS AG (CH) | 2014-05-27 | — | — | US | disclosed |
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | NOVARTIS AG (CH) | 2011-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195980-A1 | Bicyclic Kinase Inhibitors | PIM1, PIM2, PIM3 | MAPT 3216/4885ALDH1A1 2522/4885TDP1 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.